Personalis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Personalis şirketinin toplam hissedar öz sermayesi $166.8M ve toplam borcu $1.6M olup, bu da borç-öz sermaye oranını 1% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $239.9M ve $73.1M dir.

Anahtar bilgiler

1.0%

Borç/özkaynak oranı

US$1.65m

Borç

Faiz karşılama oranı	n/a
Nakit	US$143.65m
Eşitlik	US$166.76m
Toplam yükümlülükler	US$73.13m
Toplam varlıklar	US$239.89m

Son finansal sağlık güncellemeleri

Recent updates

Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Nov 19

The Proper Play On Personalis

Oct 28

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Sep 14

A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Jul 25

Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Apr 19

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Mar 02

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Dec 18

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Dec 04

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Sep 04

Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

Apr 17

The Prognosis For Personalis

Jun 16

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Jun 09

Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Feb 17

Personalis: Getting Personal Again

Feb 02

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: PSNL 'nin kısa vadeli varlıkları ( $170.3M ) kısa vadeli yükümlülüklerini ( $36.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: PSNL şirketinin kısa vadeli varlıkları ( $170.3M ) uzun vadeli yükümlülüklerini ( $36.7M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: PSNL şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: PSNL şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 1% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: PSNL şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: PSNL serbest nakit akışı her yıl % 23.6 1.8 yıl yetecek nakit akışına sahip olacaktır.

Personalis Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

Is Personalis (NASDAQ:PSNL) Using Debt In A Risky Way?

Recent updates

Personalis, Inc. (NASDAQ:PSNL) Stock's 26% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2024

The Proper Play On Personalis

Personalis, Inc. to Report Q3, 2024 Results on Nov 06, 2024

Investors Still Aren't Entirely Convinced By Personalis, Inc.'s (NASDAQ:PSNL) Revenues Despite 28% Price Jump

Personalis, Inc. announced that it expects to receive $17.745 million in funding from Tempus AI, Inc

Personalis, Inc. Revises Earnings Guidance for the Year 2024

A Piece Of The Puzzle Missing From Personalis, Inc.'s (NASDAQ:PSNL) 131% Share Price Climb

Personalis, Inc. to Report Q2, 2024 Results on Aug 07, 2024

Consensus estimates of losses per share improve by 11%

Personalis, Inc. Revises Earnings Guidance for the Full Year of 2024

First quarter 2024 earnings released: US$0.26 loss per share (vs US$0.61 loss in 1Q 2023)

Personalis, Inc. to Report Q1, 2024 Results on May 08, 2024

Market Cool On Personalis, Inc.'s (NASDAQ:PSNL) Revenues Pushing Shares 25% Lower

Personalis, Inc., Annual General Meeting, May 17, 2024

Personalis, Inc. Announces Publication Validating Next Personal Test for Ultra-Sensitive MRD Detection and Cancer Treatment Response Monitoring

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 31% Yet They're Still Not Telling The Full Story

Full year 2023 earnings: EPS misses analyst expectations

Personalis, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024

Personalis, Inc. to Report Q4, 2023 Results on Feb 28, 2024

Personalis Announces Medicare Coverage for Next Dx(R) Comprehensive Genomic Tumor Profiling Assay

Personalis, Inc. Provides Unaudited Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2023

Personalis, Inc. has filed a Follow-on Equity Offering in the amount of $50 million.

Personalis, Inc.'s (NASDAQ:PSNL) Shares Leap 37% Yet They're Still Not Telling The Full Story

Will Personalis (NASDAQ:PSNL) Spend Its Cash Wisely?

Third quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Personalis, Inc. Provides Earnings Guidance for the Fourth Quarter of 2023

Personalis, Inc. Launches NeXT Personal DX for Early Access Clinical Use in Residual Disease and Recurrence Detection in Cancer

Personalis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Personalis, Inc. Announces the Presentation of Initial Findings from Its Work with the Tracerx Lung Cancer Study

Personalis, Inc. Appoints Deepshikha Bhandari as SVP, Regulatory, Quality and Clinical Compliance

Personalis (NASDAQ:PSNL) Will Have To Spend Its Cash Wisely

New minor risk - Shareholder dilution

Personalis, Inc. Provides Earnings Guidance for the Third Quarter and Full Year of 2023

Price target decreased by 13% to US$5.90

Personalis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

Personalis, Inc. Announces Board Changes

High number of new directors

Personalis, Inc. Provides Earnings Guidance for the Full Year 2023

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Investors Holding Back On Personalis, Inc. (NASDAQ:PSNL)

Consensus revenue estimates decrease by 16%, EPS upgraded

Price target decreased by 23% to US$6.80

Full year 2022 earnings: EPS misses analyst expectations

Personalis, Inc. to Report Q4, 2022 Results on Feb 23, 2023

Personalis, Inc. Provides Revenue Guidance for the Fourth Quarter Ended December 31, 2022

Personalis, Inc. Announces Retirement of John West from the Board of Directors

Price target decreased to US$8.60

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

Personalis, Inc. Appoints Christopher Hall as SVP and Head, Diagnostics Business

Personalis, Inc. to Report Q3, 2022 Results on Nov 02, 2022

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Personalis, Inc. Provides Earnings Guidance for the Year 2022

Personalis, Inc. to Report Q2, 2022 Results on Aug 03, 2022

Price target decreased to US$16.20

Personalis, Inc.(NasdaqGM:PSNL) dropped from Russell 2000 Growth Index

The Prognosis For Personalis

Health Check: How Prudently Does Personalis (NASDAQ:PSNL) Use Debt?

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Personalis, Inc. Provides Earnings Guidance for the Full Year of 2022

Price target decreased to US$21.83

High number of new directors

Co-Founder exercised options to buy US$266k worth of stock.

Personalis, Inc. to Report Q1, 2022 Results on May 04, 2022

Co-Founder notifies of intention to sell stock

Personalis Announces Issuance of Additional US Patent Related to the Next Personal Platform

Personalis, Inc., Annual General Meeting, May 17, 2022

Co-Founder notifies of intention to sell stock

High number of new directors

Full year 2021 earnings: EPS misses analyst expectations